ArticleVaccine2012
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine.Vaccines · 2026Review
- Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics · 2023Review
- Challenges and Prospects of Plant-Derived Oral Vaccines against Hepatitis B and C Viruses.Plants (Basel, Switzerland) · 2021Review
- Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.NPJ vaccines · 2021Article
- Co-Administration of Injected and Oral Vaccine Candidates Elicits Improved Immune Responses over Either Route Alone.Vaccines · 2020Article
- Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.The Journal of infectious diseases · 2019Article
- The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.mSphere · 2018Review
- Review
- A Preliminary Study of a Lettuce-Based Edible Vaccine Expressing the Cysteine Proteinase ofFrontiers in immunology · 2018Article
- Corn-based vaccines: current status and prospects.Planta · 2017Review
- Micropropagation of transgenic lettuce containing HBsAg as a method of mass-scale production of standardised plant material for biofarming purposes.Plant cell reports · 2017Article
- The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.International journal of molecular sciences · 2016Review
- Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine.Archives of biochemistry and biophysics · 2015Article
- Plant-made oral vaccines against human infectious diseases-Are we there yet?Plant biotechnology journal · 2015Review
- Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.Vaccine · 2015Article
- Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery.Human vaccines & immunotherapeutics · 2015Article
- Article
- Freeze-drying of plant tissue containing HBV surface antigen for the oral vaccine against hepatitis B.BioMed research international · 2014Article
- Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Advanced drug delivery reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatitis B remains a major global health problem despite the availability of a safe and effective vaccine. Segments of the population lack access to or respond poorly to the parenteral vaccine, perpetuating the infection-transmission cycle. A low cost, orally delivered vaccine has the potential to alleviate many of these problems. Here we describe the expression of a bioencapsulated hepatitis B surface antigen (HBsAg) in maize and its immunogenicity, demonstrating for the first time a commercially feasible oral subunit vaccine production system for a major disease. This work surmounts previous barriers to plant-produced vaccines by expressing HBsAg at much higher levels and retaining antigen immunogenicity post-processing: factors which facilitated a robust immune response in mice without the need for an adjuvant. This method provides a practical solution to the delivery of a low-cost, stable oral vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.